Cardano (ADA) Struggles to Reach $18 Target as Rexas Finance (RXS) Gains Momentum in Presale Stage 11

The top analyst has identified a bold answer as to why Cardano(ADA) will have a hard time hitting $18 and found another token that could achieve that easily.

Cardano (ADA) is currently facing an uphill battle in its quest to reach a price of $18, largely due to the astronomical market capitalization that would be required. Despite recent surges in ADA's value, fueled by a wave of optimism, the overall sentiment towards the cryptocurrency remains cautious.

However, a new token, RXS from Rexas Finance, is quickly gaining ground in the presale market, emerging as a potential "ADA killer." With a focus on real-world assets (RWA) and an impressive presale performance, RXS is attracting attention.

As of this writing, RXS is in Stage 11 of its presale, with each token priced at $0.175, set to rise to $0.20 soon.

This token is gaining massive momentum, especially among investors who have been closely following ADA's journey and are now seeking an alternative path to high returns. But, why is everyone talking about RXS as the 'ADA killer'?

Let's dive deeper into the context.

Top Analyst Claims ADA May Struggle To Hit $18, But This Token Could Reach It Easily

The top cryptocurrency, ADA, has surged in value over the past week, leaving many traders euphoric as they witness an increase of 8.25% in ADA's price over a single day. However, some traders may be setting their sights too high as they envision ADA reaching a price of $18.

This price point would propel ADA's market capitalization to a staggering height of around $608.04 billion, an 18x increase from its current valuation.

To put this into perspective, ADA's market cap would need to surpass the combined market capitalizations ofBinance Coin (BNB), XRP, Dogecoin (DOGE), Polygon (MATIC), and Tron (TRX) - a highly ambitious feat.

Moreover, ADA's price would be about 60x higher than that of XRP, the seventh-largest cryptocurrency by market capitalization.

While ADA has experienced some impressive gains recently, especially after bottoming out at around $0.24 in June 2022, and despite being touted as the 'Ethereum (ETH) killer,' reaching a price of $18 may be a distant dream in the current crypto market landscape and market sentiment.

RXS Gaining Momentum: Rexas Finance Positioned As An 'ADA Killer' With $35M Presale Success

In contrast to ADA's challenges, another token, RXS from Rexas Finance, is making headlines with its presale success, leading some analysts to dub it the 'ADA killer.'

This token is designed to capitalize on the high demand for decentralized finance (DeFi) solutions that integrate blockchain technology with real-world applications.

Specifically, Rexas Finance aims to bridge traditional assets with the blockchain, enabling users to trade stocks, commodities, and other financial instruments on-chain.

By merging these two worlds, DeFi and traditional finance, and catering to a vast market, Rexas Finance is setting itself up to compete with established cryptocurrencies like Cardano, albeit in a different domain.

According to the latest updates, the presale has managed to collect around $35 million out of the desired $41 million, indicating a strong demand for RXS tokens.

With almost 91.95% of its total amount raised, the presale has already sold more than 390 million tokens out of its total reserve of 425 million, highlighting its popularity among crypto investors.

Furthermore, in terms of visibility and credibility, the RXS token has made significant progress; it is now listed on major cryptocurrency portals like CoinMarketCap and CoinGecko and has undergone an audit by Certik, which is boosting the buzz around its legitimacy and security.

The Future For RXS And ADA

2025 is shaping up to be a bullish year for the crypto industry. While the price for Cardano (ADA) is set to rise, achieving an $18 price point seems distant based on the current crypto market, requiring more than 18X of its market cap to get there.

But for Rexas Finance, analysts have predicted that $18 seems an easy reach for it, based on the momentum where it has been selling out its presale stages very fast due to increased demand, currently in stage 11 where one RXS goes for $0.175.

However, savvy investors should act fast before the price hikes to $0.2.